Skip to main content

Table 2 MTX-related toxicities and outcome

From: High-dose methotrexate in ICU patients: a retrospective study

N (%) or median (IQR)Survivors
n = 23
Non survivors
n = 10
P value
MTX infusion
 Median dose (g)7.4 [4.9–14]5.85 [5.1–10.5]0.814
 Time since ICU admission (days)4 [1–7]4 [2.2–8.7]0.335
Interacting medications
 Mean number of medications (sd)0.69 (0.89)0.8 (0.92)0.578
  Piperacillin-tazobactam44 
  Proton-pump inhibitors63 
  Levetiracetam40 
MTX-related complications18 (78%)9 (90%)0.76
 Includinga   
 Acute kidney injury7 (30%)4 (40%) 
 Mucositis15 (65%)6 (60%) 
 Diarrhea6 (26%)8 (80%) 
 Liver tests disturbances11 (48%)4 (40%) 
MTX concentrations (µmol/L)
 MTX H243.1 [1.5–5.62]19.5 [6.2–29.4]0.052
 MTX H365.4 [3–7.7]16.7 [2.23–44.2]0.643
 MTX H480.4 [0.3–0.7]1.6 [0.6–5.9]0.103
 MTX H720.3 [0.1–0.4]0.6 [0.2–3.9]0.143
 MTX H960.07 [0.02–0.12]0.34 [0.26–1.25]0.013
Specific treatments
 Median dose of folinic acid rescue (mg)200 [200–200]320 [200–800]0.003
 Carboxypeptidase1 (4.3%)2 (20%)0.436
Outcomes
 Length of ICU stay (days)10 [6–18.5]19.5 [10.7–25]0.16
 Length of hospital stay64.5 [37–103]36 [29–72.7]0.13
 End of life decision2 (9%)9 (90%)< 0.001
  1. MTX methotrexate, ICU intensive care unit
  2. aSome patients experienced several MTX-related complications